Compared with tigecycline/harmaline monotherapy, the combination therapy significantly suppressed TNF-α and IL-1β levels and promoted IL-10 production, suggesting that harmaline is also involved in tigecycline modulation of the immune response to infection (Fig. 11D through F). This evidence concerns the gene IL10 and infection.